Grim19 attenuates DSS induced colitis in an animal model

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Kim, Jae Kyung ^a   Lee, Seung Hoon ^a   Lee, Seon Young ^a   Kim, Eun Kyung ^a   Kwon, Jeong Eun ^a   Seo, Hyeon Beom ^a   Lee, Han Hee ^b   Lee, Bo In ^b   Park, Sung Hwan ^a,b   Cho, Mi La ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; GENE ASSOCIATED WITH RETINOID INTERFERON INDUCED MORTALITY 19; INTERLEUKIN 17; INTERLEUKIN 1BETA; PROTEIN INHIBITOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GRIM19 PROTEIN, MOUSE; OXIDOREDUCTASE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; HUMAN; HUMAN CELL; INTESTINAL TISSUE; LYMPH NODE; NONHUMAN; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLON; GENETICS; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NADH, NADPH OXIDOREDUCTASES; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84973454125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155853     Document Type: Article

References (29)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641-1657. PMID: 17499606
2. Fitzpatrick LR. Inhibition of IL-17 as a pharmacological approach for IBD. Int Rev Immunol. 2013; 32:544-555. doi: 10.3109/08830185.2013.821118 PMID: 23886112
3. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011; 140:1756-1767. doi: 10.1053/j.gastro.2011.02.016 PMID: 21530742
4. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. Open J Immunol. 2006; 176:5652-5661.
5. Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. Open J Immunol. 2007; 178:4901-4907.
6. Yan JW, Wang YJ, Peng WJ, Tao JH, Wan YN, Li BZ, et al. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases. Expert Opin Ther Targets. 2014; 18:29-41. doi: 10.1517/14728222.2013.843669 PMID: 24147601
7. Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Lango Allen H, De Franco E, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014; 46:812-814. doi: 10.1038/ng.3040 PMID: 25038750
8. Cenit MC, Alcina A, Marquez A, Mendoza JL, Diaz-Rubio M, de las Heras V, et al. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. Genes Immun. 2010; 11:264-268. doi: 10.1038/gene.2010.10 PMID: 20200543
9. Zhang J, Wu J, Peng X, Song J, Wang J, Dong W. Associations between STAT3 rs744166 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. PLoS One. 2014; 9:e109625. doi: 10.1371/journal.pone.0109625 PMID: 25286337
10. Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, et al. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res. 2007; 27:3749-3756. PMID: 17970038
11. Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, et al. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PLoS One. 2015; 10:e0135858. doi: 10.1371/journal.pone.0135858 PMID: 26360050
12. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem. 2000; 275:33416-33426. PMID: 10924506
13. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Nati Acad Sci U S A. 2003; 100:9342-9347.
14. Moon YM, Lee J, Lee SY, Her YM, Ryu JG, Kim EK, et al. Gene associated with retinoid-interferon-induced mortality 19 attenuates murine autoimmune arthritis by regulation of th17 and treg cells. Arthritis Rheumatol. 2014; 66:569-578. doi: 10.1002/art.38267 PMID: 24574216
15. Okamoto T, Inozume T, Mitsui H, Kanzaki M, Harada K, Shibagaki N, et al. Overexpression of GRIM-19 in cancer cells suppresses STAT3-mediated signal transduction and cancer growth. Mol Cancer Ther. 2010; 9:2333-2343. doi: 10.1158/1535-7163.MCT-09-1147 PMID: 20682646
16. Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Munivenkatappa R, et al. Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice. Proc Nati Acad Sci U S A. 2013; 110: E4213-4222.
17. Barnich N, Hisamatsu T, Aguirre JE, Xavier R, Reinecker HC, Podolsky DK. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem. 2005; 280:19021-19026. PMID: 15753091
18. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006; 131:1812-1825. PMID: 17087945
19. Ekchariyawat P, Thitithanyanont A, Sirisinha S, Utaisincharoen P. Involvement of GRIM-19 in apoptosis induced in H5N1 virus-infected human macrophages. Innate immunity. 2013; 19:655-662. doi: 10.1177/1753425913479149 PMID: 23529854
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9:798-809. doi: 10.1038/nrc2734 PMID: 19851315
21. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94:174-181. PMID: 8403503
22. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol. 2008; 14:5110-5114. PMID: 18777586
23. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011; 5:185-210. doi: 10.2147/DDDT.S11290 PMID: 21552489
24. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010; 24:157-165. doi: 10.1016/j.bpg.2009.10.011 PMID: 20227029
25. Vuitton L, Koch S, Peyrin-Biroulet L. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr Drug Targets. 2013; 14:1385-1391. PMID: 23627915
26. Yan S, Li Z, Thiele CJ. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Oncotarget. 2013; 4:433-445. PMID: 23531921
27. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999; 10:39-49. PMID: 10023769
28. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine. 2004; 26:45-56. PMID: 15050604
29. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. 2009; 206:1465-1472. doi: 10.1084/jem.20082683 PMID: 19564350